It recorded a net loss of $71.2 million. Diluted earnings per share were -$2.06. Across the 8 fiscal years shown, revenue grew from $23.2 million in fiscal 2017 to $65.3 million in fiscal 2024, about 15.9% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
0
-100.0%
|
65
+33.8%
|
49
+19.9%
|
41
+17.0%
|
35
+25.4%
|
28
+464.7%
|
5
+203.0%
|
2
-93.0%
|
23
|
| Cost of revenue |
—
|
—
|
—
|
—
|
0
-100.0%
|
1
-47.3%
|
3
-37.3%
|
4
|
—
|
—
|
| Gross profit |
—
|
—
|
—
|
—
|
41
+21.9%
|
33
+33.1%
|
25
+3747.4%
|
1
|
—
|
—
|
| Research and development |
0
-96.9%
|
4
-76.3%
|
17
-68.4%
|
52
-38.8%
|
86
+23.4%
|
69
+103.7%
|
34
+5.5%
|
32
+89.6%
|
17
+135.4%
|
7
-46.0%
|
| Selling, general and administrative |
12
-11.0%
|
14
-41.9%
|
23
-29.7%
|
33
+8.5%
|
31
+25.1%
|
24
+46.0%
|
17
+14.5%
|
15
+49.1%
|
10
+13.4%
|
9
+13.5%
|
| Operating income |
-67
-281.4%
|
-17
-220.0%
|
15
+139.6%
|
-37
+51.3%
|
-75
-24.9%
|
-60
-135.1%
|
-26
+44.4%
|
-46
-61.8%
|
-29
-1299.1%
|
2
+111.4%
|
| Other income (expense) |
-5
-402.8%
|
2
-53.3%
|
3
-34.3%
|
5
-76.6%
|
21
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
-71
-346.2%
|
-16
-189.7%
|
18
+155.8%
|
-32
+41.5%
|
-54
-31.8%
|
-41
+12.4%
|
-47
-180.5%
|
-17
+58.0%
|
-40
-1600.7%
|
3
+112.8%
|
| Income tax |
0
|
0
|
0
|
0
|
0
-100.0%
|
0
+700.0%
|
0
+0.0%
|
0
+0.0%
|
0
+0.0%
|
0
+0.0%
|
| Net income |
-71
-346.2%
|
-16
-188.6%
|
18
+156.2%
|
-32
+40.7%
|
-54
-31.7%
|
-41
+13.1%
|
-47
-180.5%
|
-17
+58.0%
|
-40
-1600.7%
|
3
+112.8%
|
| Basic EPS |
-2.06
+13.8%
|
-2.39
-189.5%
|
2.67
+155.9%
|
-4.78
+45.4%
|
-8.75
-2264.9%
|
-0.37
+28.8%
|
-0.52
-116.7%
|
-0.24
+75.3%
|
-0.97
-1485.7%
|
0.07
|
| Diluted EPS |
-2.06
+13.8%
|
-2.39
-189.5%
|
2.67
+155.9%
|
-4.78
+52.2%
|
-9.99
-1565.0%
|
-0.60
-15.4%
|
-0.52
+30.7%
|
-0.75
+22.7%
|
-0.97
-1485.7%
|
0.07
|
| Weighted average shares, basic |
35
+418.7%
|
7
+0.0%
|
7
+0.0%
|
7
+7.1%
|
6
-94.5%
|
113
+23.5%
|
91
+28.0%
|
71
+71.7%
|
41
+12.5%
|
37
|
| Weighted average shares, diluted |
35
+418.7%
|
7
+0.0%
|
7
+0.0%
|
7
+6.5%
|
6
-94.5%
|
114
+25.7%
|
91
+25.8%
|
72
+74.7%
|
41
+12.2%
|
37
|
| Other measures | ||||||||||
| Depreciation and amortization |
0
-100.0%
|
0
-3.9%
|
0
-0.8%
|
0
+18.4%
|
0
+14.4%
|
0
+161.5%
|
0
+36.2%
|
0
+50.9%
|
0
-37.6%
|
0
+46.6%
|
| EBITDA |
-67
-289.6%
|
-17
-214.5%
|
15
+141.0%
|
-36
+51.6%
|
-75
-25.0%
|
-60
-135.0%
|
-26
+44.6%
|
-46
-61.8%
|
-29
-1255.7%
|
2
+111.8%
|
| Margins | ||||||||||
| Gross margin |
—
|
—
|
—
|
—
|
100.00%
|
95.95%
|
90.38%
|
13.27%
|
—
|
—
|
| Operating margin |
—
|
—
|
22.27%
|
-75.31%
|
-185.48%
|
-173.65%
|
-92.58%
|
-940.90%
|
-1,762.39%
|
10.25%
|
| Pretax margin |
—
|
—
|
27.23%
|
-65.22%
|
-133.80%
|
-118.71%
|
-169.95%
|
-342.20%
|
-2,470.28%
|
11.48%
|
| Profit margin |
—
|
—
|
27.57%
|
-65.55%
|
-132.69%
|
-117.83%
|
-169.96%
|
-342.20%
|
-2,470.28%
|
11.48%
|
| EBITDA margin |
—
|
—
|
22.86%
|
-74.52%
|
-184.68%
|
-172.83%
|
-92.19%
|
-939.27%
|
-1,759.12%
|
10.62%
|
| Effective tax rate |
—
|
—
|
0.00%
|
—
|
—
|
—
|
—
|
—
|
—
|
0.04%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- LITS (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1262104
- Former names
- MEI Pharma, Inc. (until Sep 10, 2025); MARSHALL EDWARDS INC (until Jun 6, 2012)
Other Finance Services companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.